Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

195.91 -0.61 (-0.31%)

Streaming Delayed Price Updated: 10:50 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

What's going on in today's session: S&P500 gap up and gap down stocks ↗

December 10, 2025

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.

Via Chartmill

1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds

December 07, 2025

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗

December 05, 2025

The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.

Via The Motley Fool

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal ↗

October 24, 2025

Via Stocktwits

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

December 01, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint

November 24, 2025

Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement...

Via MarketMinute

Which S&P500 stocks are moving before the opening bell on Monday? ↗

November 24, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Via Chartmill

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

November 24, 2025

From Biogen Inc.

Via GlobeNewswire

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy Government World Trade

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

November 20, 2025

From Biogen Inc.

Via GlobeNewswire

Uncover the latest developments among S&P500 stocks in today's session. ↗

November 18, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Completes Acquisition of Alcyone Therapeutics

November 14, 2025

From Biogen Inc.

Via GlobeNewswire

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call

November 06, 2025

Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple...

Via StockStory

Topics Earnings

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

November 03, 2025

From Biogen Inc.

Via GlobeNewswire

BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands

October 31, 2025

Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above...

Via StockStory

Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations

October 30, 2025

Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was...

Via StockStory

Topics Artificial Intelligence

Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide ↗

October 30, 2025

Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge.

Via Investor's Business Daily

Examining the Future: Biogen's Earnings Outlook ↗

October 29, 2025

Via Benzinga

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

October 28, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗

October 24, 2025

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.

Via Benzinga

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

October 24, 2025

From Biogen Inc.

Via GlobeNewswire

3 Profitable Stocks We Steer Clear Of

October 24, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

October 22, 2025

From Biogen Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.